Veloxis pays over $46 million and enters deferred prosecution over kickbacks
Veloxis Pharmaceuticals Inc. has agreed to pay more than $46 million to resolve criminal and civil allegations that it paid kickbacks to boost prescriptions of its kidney transplant drug Envarsus XR. The resolution includes a deferred prosecution agreement, a $34.45 million False Claims Act settlement and a $1.55 million Sunshine Act penalty — the largest since the law's passage.
Veloxis Pharmaceuticals Inc., a drug manufacturer based in Cary, North Carolina, has agreed to pay more than $46 million to resolve criminal and civil allegations that it paid kickbacks to induce prescriptions and purchases of Envarsus XR, a kidney transplant immunosuppressant, the Department of Justice announced on August 10, 2026. The company entered a deferred prosecution agreement tied to a criminal information filed in the District of Massachusetts charging it with conspiracy to violate the Anti-Kickback Statute, and agreed to a criminal penalty of more than $10 million. It will also pay $34.45 million to resolve False Claims Act allegations and a $1.55 million civil penalty to CMS.
From October 2016 until around June 2023, Veloxis and its employees paid kickbacks to transplant healthcare providers to win prescriptions for Envarsus against a cheaper generic competitor. The inducements included lavish meals, expensive trips and resort stays presented as advisory boards, gifts, and consulting payments for work that was never performed. Employees falsified expense reports to conceal the payments, including by adding names to attendee lists to lower the apparent cost per head and omitting physicians' names to avoid reporting obligations. As a result, the company under-reported or failed to report payments under the Open Payments Program, known as the Sunshine Act. Veloxis also admitted paying specialty pharmacies per-patient monthly fees, described as payments for data or adherence services, to induce them to buy Envarsus regardless of whether those services were delivered.
Veloxis admitted liability and accepted responsibility. The department said the company received cooperation credit for proactively disclosing inculpatory evidence, facilitating employee interviews and taking remedial steps, including terminating the employees responsible.
The department said the $1.55 million penalty is the largest Sunshine Act recovery since the law was enacted in 2010, signalling that inaccurate Open Payments reporting is now being pursued as a standalone enforcement risk alongside kickback liability. Officials from the Civil Division, the US Attorney's Office for the District of Massachusetts, the FBI and HHS-OIG each framed the case as a warning to companies that try to influence prescribing through perks.
Veloxis has entered a five-year Corporate Integrity Agreement with HHS-OIG requiring an enhanced compliance programme and a review by an independent compliance expert. Part of the civil resolution settles claims brought under the qui tam provisions of the False Claims Act. The criminal case remains subject to the terms of the deferred prosecution agreement.
Cite this report
The Precedent. "Veloxis pays over $46 million and enters deferred prosecution over kickbacks." September 11, 2026. https://theprecedent.org/article/veloxis-pays-over-46-million-and-enters-deferred-prosecution-over-kickbacks
